Skip to main content
OpenTrials
Completed

NCT Number: NCT00652483

Safety and Efficacy Study of Brimonidine in Patients With Glaucoma or Ocular Hypertension

This study evaluates the safety and efficacy of brimonidine 0.1% ophthalmic solution compared with brimonidine 0.2% ophthalmic solution in patients with glaucoma or ocular hypertension

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Glaucoma Eye Diseases Ocular Hypertension

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Atlanta, Georgia, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Ocular hypertension or glaucoma in both eyes

Exclusion criteria

  • Uncontrolled systemic disease
  • Known allergy or sensitivity to brimonidine

Treatment and study plan

Brimonidine ophthalmic solution 0.1%

Drug

1 drop instilled in each eye 3 times daily (08:00, 14:00, 20:00)

Brimonidine ophthalmic solution 0.2%

Drug

1 drop instilled in each eye 3 times daily (08:00, 14:00, 20:00)

Other names: ALPHAGAN®

Primary outcomes

  1. Intraocular pressure (IOP)

    Time frame: Week 2 - Month 3

Secondary outcomes

  1. IOP

    Time frame: Month 6 - Month 12

Sponsors and collaborators

Lead sponsor

Allergan

Industry

Registry information

Important dates

Study start
2003
Primary completion
2003
Study completion
2004
First posted
Apr 3, 2008
Registry last updated
Apr 3, 2008

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.